Addressing Europe’s obesity burden, French MedTech startup Annette closes €2 million round for structured GLP-1 support

Annette, a Paris-based clinical assistance system devoted to persistent weight problems treatment and people making use of GLP-1 therapies, has actually elevated EUR2 million to supply a follow-up supplied by a professional group and worked with via a professional friend application.

The round was led by Redstone, Ring Resources and AFI Ventures (Ventech– beginning fund) Clover VC, and Gfund.

“ We utilize both scientific and subjective information (satiation, power, signs …) to synchronise the treatment group around each individual, find very early signals, and change at the best minute. Innovation serves as a safeguard: it increases the human touch– it never ever changes it,” states Gwen Le Calvez, founder and Principal Item and Innovation Policeman, Annette.

Annette’s EUR2 million raising comes in the middle of a stable circulation of 2025 European financing right into electronic chronic-care and obesity-related HealthTech.

In Poland, Holi protected EUR3 million to increase its data-driven electronic weight problems facility throughout Europe, while Doctor.One elevated EUR4 million to scale its asynchronous chronic-care version, that includes assistance for metabolic and obesity-related problems. In France– Annette’s home market– RDS elevated EUR14 million to industrialise its remote-monitoring spot, signalling recurring capitalist self-confidence in French HealthTech framework a lot more extensively.

With Each Other, these 2025 rounds total up to about EUR21 numerous resources circulations in nearby chronic-care and surveillance services, increasing to ~ EUR23 million when consisting of Annette.

Within this context, Annette sticks out as one of minority French firms especially targeting GLP-1– sustained weight problems treatment, and its raising lines up with the bigger 2025 fad in the direction of incorporated, multidisciplinary chronic-care systems throughout Europe.

“ These outcomes are not driven by the therapy alone: they happen when drug is coupled with framework, dietary support, psychological assistance, and a steady adjustment to the body’s rhythm. This is exactly what Annette supplies– transforming a therapy right into a real long-lasting treatment path,” includes François-Xavier Trancart, founder and chief executive officer, Annette.

Established In 2024 by 2 repeat business owners– François-Xavier Trancart (Artsper) and Gwen Le Calvez (Birdie)– Annette frameworks long-lasting GLP-1 and persistent weight problems treatment via a multidisciplinary group worked with through a companion-app, guaranteeing therapy safety and security and aiding people attain long lasting outcomes.

Annette gives a companion-app created as an all-natural expansion of treatment for people beginning GLP-1 therapies. The system arranges GLP-1 follow-up around a multidisciplinary scientific group:

• A personal messaging network with Annette specialists (dietitians, exercise trains, psycho therapists, and so on)
• Guided paths customized to every stage of the therapy
• Surveillance of crucial physical signals: appetite, satiation, power, food digestion, therapy adherence
• Advice towards a doctor for assessment, dosage changes, or stabilisation
• An encouraging neighborhood, so people never ever advance alone

Today, greater than 1,000 people are sustained via Annette, which supposedly flaunts an average weight loss above clinical trial outcomes, a 90% retention price at 3 months, and an NPS of +70.

Annette’s currentcare version is based upon a EUR49 regular monthly membership.

“ At AFI Ventures, we back business owners that utilize modern technology to take on culture’s most important obstacles. Weight problems is plainly among them. What makes us specifically passionate concerning Annette is the unusual mix of an enthusiastic vision, clinical roughness, and an item with the ability of producing purposeful effect for countless individuals. We are persuaded that the Annette group is developing an option that can genuinely relocate the needle,” states Constantin de Chaudenay, Capitalist at AFI Ventures

Weight problems is a persistent and multifactorial illness, affected by biology, feelings, and atmosphere. It is currently recognided as a significant public health and wellness concern in France and throughout Europe. According to the 2024 nationwide OFÉO research study:

• 48.8% of grownups in France are obese or coping with weight problems
• consisting of 18% with weight problems– that is virtually 10 million individuals

Annette describes that if treatment paths do not boost, the occurrence of weight problems can get to 30% of the populace by 2030.

The arrival of GLP-1 therapies (Wegovy, Mounjaro) notes a significant landmark, yet the business lays out that global experience has actually revealed the threats when these medicines are utilized without correct guidance: separated prescriptions, absence of follow-up, and substantial weight restore.

Without dietary framework, psychological assistance, customized exercise, and recurring clinical follow-up, the advantages discolor and the danger of restore boosts. This is exactly where Annette wants to can be found in.

“ The therapy can lower hunger. Yet it does not revise consuming behaviors or the connection with one’s body. Medical and behavior assistance makes it feasible to change exactly how one consumes, relocates, and really feels. It is the mix of both that genuinely moves the weight trajectory– and makes it last,” describes Dr Lysiane Jubin, Principal Medical Policeman, Annette.

This brand-new financing round will certainly make it possible for Annette to scale its version to 10s of countless people, in France and after that throughout Europe, concentrating on 3 top priorities:

• Speeding up the scientific companion-app (personalisation, follow-up, stablizing).
• Increasing and working with the multidisciplinary clinical network, in close cooperation with medical care medical professionals.
• Reinforcing avoidance and education and learning around weight problems and the accountable use GLP-1 therapies.

The message Addressing Europe’s obesity burden, French MedTech startup Annette closes €2 million round for structured GLP-1 support showed up initially on EU-Startups.